Jefferies Raises PT and Estimates on Gilead Sciences (GILD); Stribild (Quad Pill) Approved

August 28, 2012 7:23 AM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $105.54 +3.07%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 43 | New: 52
Trade GILD Now!
Join SI Premium – FREE
Jefferies maintains a 'Hold' on Gilead Sciences (NASDAQ: GILD) price target of $55.00 (from $53.00).

Analyst, Thomas Wei, said, "The FDA approved GILD's Stribild (quad pill) with a label that was largely in line with expectations. GILD announced Stribild pricing of $28,500/year, which represents a premium to our assumption of $22,263. We are raising our PT to $55 on the basis of Stribild pricing, but we remain cautious on GILD based on valuation."

FY12 EPS estimate raised from $3.78 to $3.79 and FY13 from $4.05 to $4.12.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $57.19 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment